Sugi Predict

Sugi Predict / Compounds / SCHEMBL2008253

SCHEMBL2008253

SCHEMBL2008253

O=C(O)c1c(F)cc([N+](=O)[O-])cc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.55
▸ CA2 P00918 1/20 0.55
▸ TDP1 Q9NUW8 3/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ TP53 P04637 1/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CYP19A1 P11511 1/20 0.43
▸ KMT2A Q03164 5/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ HIF1A Q16665 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ TTR P02766 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL31538141 0.87 CA1 (0.47) CA1CA2TDP1CYP1A2CYP2C9
SCHEMBL15727754 0.87 CA1 (0.47) CA1CA2TDP1CYP1A2CYP2C9
SCHEMBL26926562 0.83 VCAM1 (0.47) CA1CA2TDP1CYP1A2CYP2C9
SCHEMBL31509456 0.82 MAPK1 (0.47) CA1CA2TDP1CYP1A2CYP2C9
SCHEMBL30717143 0.82 ALDH1A1 (0.47) CA1CA2TDP1CYP1A2CYP2C9
SCHEMBL1740988 0.79 ALDH1A1 (0.46) CA1CA2TDP1TP53CYP3A4
SCHEMBL20298758 0.77 ALDH1A1 (0.49) CA1CA2TDP1CYP1A2CYP2C9
SCHEMBL30954040 0.77 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
SCHEMBL11317378 0.77 CA1 (0.56) CA1CA2TDP1CYP1A2CYP2C9
SCHEMBL28718422 0.77 CA1 (0.79) CA1CA2TDP1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098029-A1 KIF18A INHIBITORS AMGEN INC. (US) 2026-04-09 — — US disclosed
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
US-20260062430-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
US-12509442-B2 KIF18A inhibitors AMGEN INC. (US) 2025-12-30 — — US disclosed
US-12459932-B2 KIF18A inhibitors AMGEN INC. (US) 2025-11-04 — — US disclosed
US-12391709-B2 Inhibitors of KIF18A and uses thereof ACCENT THERAPEUTICS, INC. (US) 2025-08-19 — — US disclosed
EP-4572855-A1 INHIBITORS OF KIF18A AND USES THEREOF Accent Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
US-20250197428-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-19 — — US disclosed
EP-4551571-A1 OXAZOLE TRPML1 AGONISTS AND USES THEREOF Libra Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
CN-113226473-B KIF18A inhibitors 美国安进公司 2025-05-13 — — CN disclosed
CN-113226473-A KIF18A inhibitors 美国安进公司 2021-08-06 — — CN disclosed
US-20200239441-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-07-30 — — US disclosed
WO-2020132648-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-06-25 — — WO disclosed
WO-2020132651-A1 KIF18A INHIBITORS AMGEN INC. (US) 2020-06-25 — — WO disclosed
US-20120322768-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING PROTOZOAN INFECTIONS QUEEN MARY & WESTFIELD COLLEGE (GB) 2012-12-20 — — US disclosed
WO-2011066416-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PROTOZOAN INFECTIONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2011-06-03 — — WO disclosed
EP-0880508-B1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2003-04-16 — — EP disclosed
US-6184225-B1 ENDOTHELIAL GROWTH FACTOR INHIBITORS, ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 2001-02-06 — — US disclosed
EP-0880508-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ZENECA LIMITED (GB) 1998-12-02 — — EP disclosed
WO-1997030035-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ZENECA LIMITED (GB) 1997-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509442-B2 KIF18A inhibitors KIF18A, KIF18B, KIFC1 CA1 2993/4885CA2 1357/4885TDP1 1527/4885
US-20250197428-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF2C CA1 3997/4885CA2 3720/4885TDP1 741/4885
US-20200239441-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 CA1 3987/4885CA2 3800/4885TDP1 1274/4885
US-12391709-B2 Inhibitors of KIF18A and uses thereof KIF18A, KIF18B, KIF2C CA1 3997/4885CA2 3720/4885TDP1 741/4885
US-12459932-B2 KIF18A inhibitors KIF18A, KIF18B, KIF15 CA1 3941/4885CA2 3751/4885TDP1 1139/4885
US-20120322768-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING PROTOZOAN INFECTIONS PHOSPHO1, CYCS, DPM1 CA1 859/4885CA2 513/4885TDP1 4343/4885
US-20260098029-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIFC1 CA1 3086/4885CA2 1488/4885TDP1 1491/4885
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF5B CA1 1892/4885CA2 1135/4885TDP1 1013/4885
US-20260062430-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF5B CA1 2126/4885CA2 2263/4885TDP1 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.